Condition: Alopecia Areata · Sponsor: AbbVie
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be fo…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Total Skin and Beauty Dermatology Center /ID# 259539 | Birmingham, Alabama, United States | Active Not Recruiting |
| Duplicate_Advanced Research Associates - Glendale /ID# 259108 | Glendale, Arizona, United States | Completed |
| Southwest Skin Specialists /ID# 258234 | Phoenix, Arizona, United States | Completed |
| Alliance Dermatology and Mohs Center /ID# 258111 | Phoenix, Arizona, United States | Active Not Recruiting |
| Johnson Dermatology Clinic /ID# 259103 | Fort Smith, Arkansas, United States | Active Not Recruiting |
| Exalt Clinical Research /ID# 283814 | Chula Vista, California, United States | Not Yet Recruiting |
| Duplicate_JOSEPH RAOOF MD,INC /ID# 258031 | Encino, California, United States | Completed |
| First OC Dermatology /ID# 259220 | Fountain Valley, California, United States | Recruiting |
| University of California Irvine /ID# 259096 | Irvine, California, United States | Active Not Recruiting |
| Dermatology Research Associates /ID# 258033 | Los Angeles, California, United States | Recruiting |
| Stanford University School of Medicine - Redwood City /ID# 259542 | Redwood City, California, United States | Completed |
| Integrative Skin Science and Research /ID# 258114 | Sacramento, California, United States | Recruiting |
+ 270 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06012240